Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

ClinicalTrials.gov ID: NCT02674763

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02674763. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive disease.

Study identification

NCT ID: NCT02674763
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: ImmunoGen, Inc.; Industry
Enrollment: 62 participants

Conditions and interventions

Conditions

Acute Myeloid Leukemia

Interventions

IMGN779 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2016 (Actual)
Primary completion: Jun 2019 (Actual)
Completion: Jul 2019 (Actual)
Last update posted: Sep 4, 2019

2016 – 2019

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 7

Facility	City	State	ZIP	Site status
Comprehensive Cancer Center (UAB CCC)	Birmingham	Alabama	35294	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—
New Mexico Cancer Care Alliance	Albuquerque	New Mexico	87106	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
Knight Cancer Institute - OSHU	Portland	Oregon	97239	—
Baylor Scott & White University Medical Center	Dallas	Texas	75246	—
The University of Texas, MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02674763, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 4, 2019 · Synced Nov 12, 2026